During the past decade, Shanghai Pulmonary Hospital conducted 159 clinical trials. In the 10-year time frame, 159 clinical trials started and 27 clinical trials were completed, i.e. on average, 17% percent of trials that started reached the finish line to date. In the past 5 years, 90 clinical trials started and 10 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shanghai Pulmonary Hospital" #1 sponsor was "Shanghai Pulmonary Hospital, Shanghai, China" with 48 trials, followed by "Hoffmann-La Roche" with 12 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 11 trials sponsored, "Tongji University" with 10 trials sponsored and "Actelion" with 10 trials sponsored. Other sponsors include 109 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shanghai Pulmonary Hospital" #1 collaborator was "Shanghai Pulmonary Hospital, Shanghai, China" with 7 trials as a collaborator, "Anhui Chest Hospital" with 3 trials as a collaborator, "Huashan Hospital" with 3 trials as a collaborator, "No.85 Hospital, Changning, Shanghai, China" with 3 trials as a collaborator and "Shanghai Public Health Clinical Center" with 3 trials as a collaborator. Other collaborators include 74 different institutions and companies that were collaborators in the rest 75 trials.

According to Clinical.Site data, the most researched conditions in "Shanghai Pulmonary Hospital" are "Carcinoma, Non-Small-Cell Lung" (17 trials), "Non-small Cell Lung Cancer" (15 trials), "Pulmonary Arterial Hypertension" (15 trials), "Non-Small Cell Lung Cancer" (12 trials) and "Bronchiectasis" (11 trials). Many other conditions were trialed in "Shanghai Pulmonary Hospital" in a lesser frequency.

Most popular intervention types in "Shanghai Pulmonary Hospital" are "Drug" (163 trials), "Procedure" (15 trials), "Other" (13 trials), "Device" (8 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Carboplatin" (14 trials), "Pemetrexed" (10 trials), "Cisplatin" (9 trials) and "Atezolizumab" (7 trials). Other intervention names were less common.

The vast majority of trials in "Shanghai Pulmonary Hospital" are 204 trials for "All" genders.

Currently, there are 104 active trials in "Shanghai Pulmonary Hospital". 12 are not yet recruiting, 63 are recruiting, 25 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 57 completed trials in Shanghai Pulmonary Hospital, 1 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Shanghai Pulmonary Hospital, 27 "Phase 1" clinical trials were conducted, 55 "Phase 2" clinical trials and 75 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 21 trials, and there were also 16 trials that are defined as “Not Applicable".

Shanghai Pulmonary Hospital has several departments that took part in Clinical trials: "Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center," - 7 trials, "Department of Nuerology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine" - 6 trials, "Department of Colorectal Surgery Fudan University Shanghai Caner Center" - 5 trials, "Suining County Center for Disease Control and Prevention" - 3 trials, "Department of Oral and Maxillofacial Implantology" - 2 trials, "PLA Cancer Centre of Nanjing Bayi Hospital ( Site 0110)" - 2 trials